Back to the future: oral targeted therapy for RA and other autoimmune diseases
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Back to the future: oral targeted therapy for RA and other autoimmune diseases
Authors
Keywords
-
Journal
Nature Reviews Rheumatology
Volume 9, Issue 3, Pages 173-182
Publisher
Springer Nature
Online
2013-02-19
DOI
10.1038/nrrheum.2013.7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sorafenib in hepatocellular carcinoma
- (2014) Debra H Josephs et al. BRITISH JOURNAL OF HOSPITAL MEDICINE
- JAKs and STATs in Immunity, Immunodeficiency, and Cancer
- (2013) John J. O'Shea et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year
- (2012) F. Vincenti et al. AMERICAN JOURNAL OF TRANSPLANTATION
- JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production
- (2012) Timothy P. LaBranche et al. ARTHRITIS AND RHEUMATISM
- JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
- (2012) A. Tefferi BLOOD
- Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion
- (2012) Paul M. Barr et al. CLINICAL IMMUNOLOGY
- Novel small-molecular therapeutics for rheumatoid arthritis
- (2012) Roy Fleischmann CURRENT OPINION IN RHEUMATOLOGY
- PKCθ: a new target for selective immunosuppression
- (2012) Amnon Altman et al. Expert Review of Clinical Immunology
- JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
- (2012) John J. O'Shea et al. IMMUNITY
- Tec Family Kinases in Inflammation and Disease
- (2012) Nicole J. Horwood et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF- B Pathways
- (2012) X. Wu et al. MOLECULAR CANCER THERAPEUTICS
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protein Kinase C Inhibition Ameliorates Posttransplantation Preservation Injury in Rat Renal Transplants
- (2012) Tom Florian Fuller et al. TRANSPLANTATION
- A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
- (2011) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
- (2011) Roy Fleischmann et al. ARTHRITIS AND RHEUMATISM
- The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells
- (2011) Keisuke Maeshima et al. ARTHRITIS AND RHEUMATISM
- Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors
- (2011) Alaric J. Dyckman et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Tec family kinases Itk and Rlk / Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates
- (2011) Julio Gomez-Rodriguez et al. FEBS Journal
- Tec family kinases: regulation of FcεRI-mediated mast-cell activation
- (2011) Wilfried Ellmeier et al. FEBS Journal
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
- (2011) Kamran Ghoreschi et al. JOURNAL OF IMMUNOLOGY
- Possible role of the JAK/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus
- (2011) M Kawasaki et al. LUPUS
- Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
- (2011) Yoshiya Tanaka et al. ARTHRITIS CARE & RESEARCH
- Optimal case definitions of upper extremity disorder for use in the clinical treatment and referral of patients
- (2011) Keith T. Palmer et al. ARTHRITIS CARE & RESEARCH
- Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the Second Childhood Arthritis and Rheumatology Research Alliance Consensus Conference
- (2011) Adam M. Huber et al. ARTHRITIS CARE & RESEARCH
- A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis
- (2011) Kristine L Stump et al. ARTHRITIS RESEARCH & THERAPY
- The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
- (2011) Betty Y Chang et al. ARTHRITIS RESEARCH & THERAPY
- Intravenous immunoglobulin does not prevent recurrence of congenital heart block in children of SSA/Ro-positive mothers
- (2010) Monika ØStensen ARTHRITIS AND RHEUMATISM
- An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents
- (2010) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Kinase inhibitors: a new approach to rheumatoid arthritis treatment
- (2010) Stanley Cohen et al. CURRENT OPINION IN RHEUMATOLOGY
- Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice
- (2010) S. Wang et al. LUPUS
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- T Cell Activation
- (2009) Jennifer E. Smith-Garvin et al. Annual Review of Immunology
- The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
- (2009) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- The tyrosine kinase network regulating mast cell activation
- (2009) Alasdair M. Gilfillan et al. IMMUNOLOGICAL REVIEWS
- Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial
- (2008) Michael E. Weinblatt et al. ARTHRITIS AND RHEUMATISM
- An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus
- (2008) Frances Rena Bahjat et al. ARTHRITIS AND RHEUMATISM
- The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia
- (2008) Elizabeth Kudlacz et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More